A real-world observational study comparing cardiovascular outcomes in patients with type 2 diabetes initiating mixed insulin versus newer oral antidiabetic agents as first injectable therapy

This retrospective observational investigation comprehensively compared cardiovascular event rates among individuals with Type 2 Diabetes Mellitus (T2DM) whose first injectable therapeutic regimen consisted of either premixed insulin or contemporary oral glucose-lowering medications, specifically sodium-glucose cotransporter-2 inhibitors (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1 RA). Data from 427 patients managed at a single center were critically analyzed from August 2024 to November 2025. The principal endpoint comprised a composite of heart failure hospitalization, non-fatal acute myocardial infarction, or non-fatal cerebrovascular accident. After statistical adjustment for baseline variables via propensity score matching, initiation of contemporary oral agents (n=142) was strongly associated with a substantially lower occurrence of the primary cardiovascular composite compared to initiation of premixed insulin (n=142) (12.0% versus 22.5%; Hazard Ratio: 0.48; 95% Confidence Interval: 0.29–0.79). This divergence was predominantly attributable to a profoundly pronounced decrease in hospitalizations for heart failure (3.5% versus 12.0%; Hazard Ratio: 0.28). Glycemic management, assessed by HbA1c reduction, was significantly more effective with contemporary oral agents, consistently accompanied by a markedly lower incidence of significant hypoglycemic episodes. These findings from clinical practice strongly indicate that selecting newer oral agents with clearly documented cardiometabolic advantages as the initial injectable therapy may reliably confer superior cardiovascular protection relative to traditional premixed insulin, offering a highly persuasive rationale for urgently reevaluating established therapeutic sequences.